Aura Biosciences Prepares To Move Nano-Enabled Drug Delivery System Into The Clinic
This article was originally published in The Pink Sheet Daily
Biotech's nanotechnology platform enables earlier detection of cancers and distant metastases, as well as targeted drug delivery.
You may also be interested in...
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.